Ikarian Capital, LLC Protagonist Therapeutics, Inc Call Options Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $205,428 - $334,704	-11,400 Reduced 5.39%	200,000 $5.52 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $2.28 Million - $5.37 Million	211,400 New	211,400 $4.86 Million
Q2 2022 Aug 12, 2022	SELL	$7.06 - $25.52 $1.13 Million - $4.1 Million	-160,700 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$23.34 - $36.08 $788,892 - $1.22 Million	33,800 Added 26.64%	160,700 $3.81 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $1.16 Million - $2.44 Million	65,800 Added 107.69%	126,900 $4.34 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $791,245 - $3.04 Million	61,100 New	61,100 $1.08 Million

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.92B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.